Fundraising Fox
/Companies
Sign in

Biohaven

NYSE: BHVN

Connecticut, US · Founded 2022 · 405 employees on LinkedIn · 5 known investors

Find your way into Biohaven

Each arrow is one introduction. Sign up to fill in the first one.

70 people can intro you to Vlad

Ask Karthik Ardhanareeswaran to introduce you to Vlad Coric

You →Karthik · together at Yale School of Medicine →Vlad

Sign up to find every way you can get introduced to Biohaven

  • Your email: who you already know at Biohaven, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Biohaven team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Biohaven is a pharmaceutical company that discovers, develops, and commercializes medications for neurological and neuropsychiatric diseases, including epilepsy, pain, mood disorders, OCD, spinocerebellar ataxia, and spinal muscular atrophy. The company operates as a modern publicly traded entity and was acquired by Pfizer in May 2022 for approximately $13 billion.

BiotechHealthtechMedical Devices

Founders & leadership

VCVlad Coric, M.D.
Vlad Coric, M.D.Chairman & Chief Executive OfficerVlad Coric holds an M.D. and brings over 25 years of clinical and research experience in neuroscience and related therapeutic areas; as CEO and Chairman of Biohaven, he led the development of Nurtec ODT for migraine treatment, which contributed to the company's acquisition by Pfizer in 2022.

Investors · 5

Oberland Capitallisted by Oberland CapitalNew York · $50M – $300M
RA Capitallisted by RA CapitalBoston

How we know: RA Capital's portfolio page · Not right? Tell us

Sixth Streetlisted by Sixth StreetSan Francisco · $50M – $2.5B

How we know: Sixth Street's portfolio page · Not right? Tell us

BlackRockreportedMexico City

How we know: the S-1 prospectus · Not right? Tell us

Valuation · disclosed

Disclosed events
$413.4Mvaluation at IPOOct 2022 · $10.50/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Related companies · 2

Biogen IdecBiogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology. The company serves patients through research and development in the life sciences industry.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.

Companies working in the same space as Biohaven.

Frequently asked questions

What does Biohaven do?
Biohaven is a pharmaceutical company that discovers, develops, and commercializes medications for neurological and neuropsychiatric diseases, including epilepsy, pain, mood disorders, OCD, spinocerebellar ataxia, and spinal muscular atrophy. The company operates as a modern publicly traded entity and was acquired by Pfizer in May 2022 for approximately $13 billion.
Who are Biohaven's investors?
Biohaven's investors include Connecticut Innovations, Oberland Capital, RA Capital, Sixth Street, BlackRock.
Where is Biohaven headquartered?
Biohaven is headquartered in Connecticut, US.